Rhythm Pharmaceuticals (RYTM) FCF Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly FCF Margin of 72.78% for Q1 2026, up 5029.0% year-over-year from 1.42% in Q1 2025, and down 59.84% quarter-over-quarter from 45.53% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) FCF Margin (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported FCF Margin for 6 consecutive years, with 72.78% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 5029.0% year-over-year to 72.78%; the TTM figure through Mar 2026 stood at 55.06% (up 2866.0% YoY), while the FY2025 annual figure was 61.17%, up 2635.0% from the prior year.
- FCF Margin declined to 72.78% in Q1 2026 per RYTM's latest filing, from 45.53% in the prior quarter.
- Across five years, FCF Margin topped out at 365.81% in Q4 2022 and bottomed at 3588.72% in Q1 2022.
- Historically, FCF Margin has averaged 373.33% across 5 years, with a median of 121.26% in 2023.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 9224842 bps — and 2023, when it sank 48707 bps.
- Rhythm Pharmaceuticals' FCF Margin stood at 365.81% in 2022, then plunged by 133 bps to 121.26% in 2023, then surged by 57 bps to 52.6% in 2024, then grew by 13 bps to 45.53% in 2025, then sank by 60 bps to 72.78% in 2026.
- Business Quant data shows RYTM's FCF Margin at 72.78% in Q1 2026, 45.53% in Q4 2025, and 62.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -12.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.84% |
| Mar 31, 2026 | -72.78% |
| Dec 31, 2025 | -45.53% |
| Sep 30, 2025 | -62.12% |
| Jun 30, 2025 | -36.88% |
| Mar 31, 2025 | -123.07% |
| Dec 31, 2024 | -52.60% |
| Sep 30, 2024 | -73.10% |
| Jun 30, 2024 | -96.37% |
| Mar 31, 2024 | -152.30% |
| Dec 31, 2023 | -121.26% |
| Sep 30, 2023 | -127.60% |
| Jun 30, 2023 | -207.42% |
| Mar 31, 2023 | -318.53% |
| Dec 31, 2022 | 365.81% |
| Sep 30, 2022 | -1,205.44% |
| Jun 30, 2022 | -428.73% |
| Mar 31, 2022 | -3,588.72% |
| Dec 31, 2021 | -2,297.96% |
| Sep 30, 2021 | -4,905.93% |